98%
921
2 minutes
20
Background/objectives: This study evaluated the impact of influenza vaccination on mortality using real-world data and compared the effect of current-season-only vaccination versus continuous two-season vaccination.
Methods: The 2017-2019 data from the Center for Disease Control and Prevention of Shenzhen, Guangdong, China, included 880,119 individuals aged ≥65 years. The participants were divided into vaccinated and unvaccinated groups and matched using propensity scores with a 1:4 nearest-neighbor approach. Vaccinated individuals were further divided into current-season-only and continuous two-season vaccination groups, matched 1:1. Cox's multivariable proportional hazards regression models were used to assess the effect of vaccination on all-cause mortality, with Firth's penalized likelihood method applied to correct for a few events. The Fine-Gray competing risk models were used to assess the effect of vaccination on cardio-cerebral vascular disease (CCVD) mortality. Sensitivity analyses, including caliper matching, a nested case-control design, and Poisson's regression, were performed to test the robustness of the results.
Results: Influenza vaccination reduced all-cause mortality by 39% (HR = 0.61, 95% CI: 0.47-0.80) and 55% (HR = 0.45, 95% CI: 0.33-0.60) in 2017-2018 and 2018-2019, respectively. Current-season-only vaccination showed stronger protective effects than continuous two-season vaccination (HR = 0.56, 95% CI: 0.31-0.99). Influenza vaccination reduced CCVD mortality by 46% (HR = 0.54, 95% CI: 0.34-0.84) in 2018-2019. The results were consistent across the sensitivity analyses.
Conclusions: Influenza vaccination was associated with a reduced risk of all-cause and CCVD mortality in older adults, underscoring the importance of routine influenza vaccination in older populations. Stronger effects were observed for current-season-only vaccination, warranting further research to confirm the association and explore mechanisms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11860298 | PMC |
http://dx.doi.org/10.3390/vaccines13020164 | DOI Listing |
Influenza Other Respir Viruses
September 2025
Public Health Agency, Belfast, UK.
Background: We evaluated the effectiveness of the influenza vaccine programme against infection among emergency hospital admissions with respiratory conditions in Northern Ireland during the 2023/2024 influenza season.
Methods: Using a test-negative design, we compared the odds of vaccination between patients who tested positive (cases) and negative (controls) for laboratory-confirmed influenza, adjusting for confounders. VE was stratified by age group, sex and time since vaccination.
J Infect Chemother
September 2025
Department of Pediatrics, Saku Central Hospital Advanced Care Center, Nagano, Japan.
Background: Influenza remains a major public health issue, leading to millions of severe cases and many deaths annually. Although educational and childcare institutions are key transmission points for the spread of the virus in communities, few studies have comprehensively examined the vaccination rates and their determinants in these settings.
Methods: We conducted a nationwide web-based survey to assess influenza knowledge, perceptions, and determinants of vaccine hesitancy based on the 5C model among childcare and educational professionals in Japan.
Chest
September 2025
Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; School of Nursing and Midwifery, Charles Darwin University, Darwin, Northern Territory, Australia.
Background: Managing bronchiectasis exacerbations is a priority for patients/parents/caregivers of children with bronchiectasis, yet evidence-based strategies among the pediatric population remain limited.
Research Question: Does the use of a personalized, written bronchiectasis action management plan (BAMP), compared to standard care, reduce non-scheduled doctor visits among children/adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis?
Study Design And Methods: Our multicenter, double-blind, superiority, randomized controlled trial enrolled children from three Australian respiratory departments between June 2018 and December 2020. Children/adolescents aged <19 years with CSLD/bronchiectasis were randomized to receive a personalized BAMP (intervention) or standard care (controls).
J Control Release
September 2025
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; Bioinnovations in Brain Cancer, Biointerfaces Institute; The Developmental Therapeutics Program, Rogel Cancer Center; Center for RNA Biomedicine, University of Michigan, Ann Arbor, MI 48109,
Lipid nanoparticles (LNPs) have played an instrumental role in the delivery of RNA therapeutics and vaccines, including the emerging class of synthetic circular RNA (circRNA). Pulmonary vaccines hold the potential to prevent various respiratory infectious diseases, such as influenza caused by influenza infection. Here, we report the pulmonary delivery of LNPs loaded with highly stable small circRNA vaccine for influenza prevention.
View Article and Find Full Text PDFVaccine
September 2025
Institute of General Practice and Family Medicine, LMU University Hospital, LMU, Munich, Germany; German Center of Mental Health, Augsburg, Munich, Germany.
Background: Chronically ill are advised to receive annual vaccinations against Covid-19 and seasonal influenza. Furthermore, chronically ill show an increased prevalence of comorbid common mental disorders (CMDs), like depression, anxiety, and somatoform disorders. With vaccination rates remaining insufficient among these vulnerable patients, prior research assumes an association between CMDs and vaccination readiness.
View Article and Find Full Text PDF